Oryzon Genomics Statistics

Total Valuation

Oryzon Genomics has a market cap or net worth of EUR 208.12 million. The enterprise value is 218.72 million.

Market Cap	208.12M
Enterprise Value	218.72M

Important Dates

The next estimated earnings date is Monday, July 21, 2025.

Earnings Date	Jul 21, 2025
Ex-Dividend Date	n/a

Share Statistics

Oryzon Genomics has 77.51 million shares outstanding. The number of shares has increased by 5.77% in one year.

Current Share Class	77.51M
Shares Outstanding	77.51M
Shares Change (YoY)	+5.77%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	8.59%
Owned by Institutions (%)	-2.05%
Float	63.03M

Valuation Ratios

PE Ratio	n/a
Forward PE	13.85
PS Ratio	28.28
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-51.86
EV / Sales	29.72
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-3.56

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	n/a
Revenue Per Employee	156,569
Profits Per Employee	-89,740
Employee Count	47
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	-1.91M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +43.58% in the last 52 weeks. The beta is 0.44, so Oryzon Genomics's price volatility has been lower than the market average.

Beta (5Y)	0.44
52-Week Price Change	+43.58%
50-Day Moving Average	2.74
200-Day Moving Average	2.16
Relative Strength Index (RSI)	45.08
Average Volume (20 Days)	522,600

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oryzon Genomics had revenue of EUR 7.36 million and -4.22 million in losses. Loss per share was -0.07.

Revenue	7.36M
Gross Profit	7.06M
Operating Income	-4.74M
Pretax Income	-6.12M
Net Income	-4.22M
EBITDA	-4.61M
EBIT	-4.74M
Loss Per Share	-0.07

Full Income Statement

Balance Sheet

Cash & Cash Equivalents	n/a
Total Debt	n/a
Net Cash	n/a
Net Cash Per Share	n/a
Equity (Book Value)	n/a
Book Value Per Share	n/a
Working Capital	n/a

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 95.89%, with operating and profit margins of -64.40% and -57.32%.

Gross Margin	95.89%
Operating Margin	-64.40%
Pretax Margin	-83.22%
Profit Margin	-57.32%
EBITDA Margin	-62.70%
EBIT Margin	-64.40%
FCF Margin	n/a

Dividends & Yields

Oryzon Genomics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.77%
Shareholder Yield	n/a
Earnings Yield	-2.03%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a